BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT05034926
- Locations
- ๐ฌ๐ท
Local Institution - 0001, Athens, Greece
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
- Conditions
- Non-Valvular Atrial Fibrillation (NVAF)
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11776
- Registration Number
- NCT05027061
- Locations
- ๐ฏ๐ต
Local Institution, Tokyo, Japan
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT05025085
- Locations
- ๐บ๐ธ
Local Institution - 072, Cincinnati, Ohio, United States
๐บ๐ธMD Anderson Cancer Center Thoracic-Head & Neck Med Onc, Houston, Texas, United States
๐บ๐ธProvidence Cancer Institute, Portland, Oregon, United States
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT05014438
- Locations
- ๐ฉ๐ช
Private Practice - Dr. Ralph von Kiedrowski, Selters, Germany
๐บ๐ธLocal Institution - 0008, Skokie, Illinois, United States
๐บ๐ธLocal Institution - 0078, Philadelphia, Pennsylvania, United States
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT05005273
- Locations
- ๐ซ๐ท
Local Institution - 0044, Pessac, France
๐ซ๐ทLocal Institution - 0013, Suresnes, France
๐ซ๐ทLocal Institution - 0042, Toulon, France
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Nivolumab + Relatlimab Fixed Dose Combination
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1190
- Registration Number
- NCT05002569
- Locations
- ๐บ๐ธ
Saint John's Cancer Institute, Santa Monica, California, United States
๐บ๐ธWashington University School Of Medicine, Miami, Florida, United States
๐บ๐ธMoffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa, Florida, United States
Taste Assessment of Ozanimod
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT05001152
- Locations
- ๐บ๐ธ
Senopsys LLC, Woburn, Massachusetts, United States
๐บ๐ธLocal Institution - 0001, Woburn, Massachusetts, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 23
- Registration Number
- NCT04965402
- Locations
- ๐บ๐ธ
West Coast Clinical Trials Global, Cypress, California, United States
A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BMS-986177 Oral SolutionDrug: [14C]BMS-986177 Solution for InfusionDrug: BMS-986177 Spray-dried Dispersion Capsules
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT04965389
- Locations
- ๐ฌ๐ง
Local Institution, Nottingham, United Kingdom
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04956627
- Locations
- ๐บ๐ธ
Hassman Research Institute, Berlin, New Jersey, United States